Tangye S.G. Al-Herz W. Bousfiha A. et al.

Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee.

J Clin Immunol. 2020; 40: 24-64Bousfiha A. Jeddane L. Picard C. et al.

Human inborn errors of immunity: 2019 update of the IUIS Phenotypical Classification.

J Clin Immunol. 2020; 40: 66-81Dancis J. Lind J. Oratz M. et al.

Placental transfer of proteins in human gestation.

Am J Obstet Gynecol. 1961; 82: 167-171Bonilla F.A. Khan D.A. Ballas Z.K. et al.

Practice parameter for the diagnosis and management of primary immunodeficiency.

J Allergy Clin Immunol. 2015; 136 (e1181-1178): 1186-1205Orange J.S. Hossny E.M. Weiler C.R. et al.

Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.

J Allergy Clin Immunol. 2006; 117: S525-S553Friedmann D. Goldacker S. Peter H.H. et al.

Preserved cellular immunity upon influenza vaccination in most patients with common variable immunodeficiency.

J Allergy Clin Immunol Pract. 2020; 8: 2332-2340 e2335

CDC. Centers for Disease Control and Prevention: COVID-19 Vaccines While Pregnant or Breastfeeding.

(Available at:) (Accessed 21 Dec, 2021)

ACOG. American College of Obstetricians and Gynecologists (ACOG): COVID-19 Vaccination Considerations for Obstetric–Gynecologic Care.

(Available at:) (Accessed Dec 21, 2021)Shimabukuro T.T. Kim S.Y. Myers T.R. et al.

Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons.

N Engl J Med. 2021; 384: 2273-2282Goldshtein I. Nevo D. Steinberg D.M. et al.

Association between BNT162b2 vaccination and incidence of SARS-CoV-2 infection in pregnant women.

JAMA. 2021; 326: 728-735Dagan N. Barda N. Biron-Shental T. et al.

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy.

Nat Med. 2021; 27: 1693-1695Gray K.J. Bordt E.A. Atyeo C. et al.

Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study.

Am J Obstet Gynecol. 2021; 225: 303.e301-303.e317Bookstaver P.B. Bland C.M. Griffin B. et al.

A review of antibiotic use in pregnancy.

Pharmacotherapy. 2015; 35: 1052-1062Pilmis B. Jullien V. Sobel J. et al.

Antifungal drugs during pregnancy: an updated review.

J Antimicrob Chemother. 2015; 70: 14-22

Agammaglobulinemia.

Pediatrics. 1952; 9: 722-728

US Food and Drug Administration. Immune Globulins.

(Available at:) (Accessed Sep 28, 2021)

Characteristics of immunoglobulin products used to treat primary immunodeficiencies (PI). In: Foundation ID, ed.

(Available at:)Imbach P. Barandun S. d'Apuzzo V. et al.

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

Lancet (London, England). 1981; 1: 1228-1231Bussel J.B. Kimberly R.P. Inman R.D. et al.

Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura.

Blood. 1983; 62: 480-486Perez E.E. Orange J.S. Bonilla F. et al.

Update on the use of immunoglobulin in human disease: a review of evidence.

J Allergy Clin Immunol. 2017; 139: S1-S46D'Mello R.J. Hsu C.D. Chaiworapongsa P. et al.

Update on the use of intravenous immunoglobulin in pregnancy.

NeoReviews. 2021; 22: e7-e24Branch D.W. Porter T.F. Paidas M.J. et al.

Obstetric uses of intravenous immunoglobulin: successes, failures, and promises.

J Allergy Clin Immunol. 2001; 108: S133-S138Sorensen R.U. Tomford J.W. Gyves M.T. et al.

Use of intravenous immune globulin in pregnant women with common variable hypogammaglobulinemia.

Am J Med. 1984; 76: 73-77Berger M. Cupps T.R. Fauci A.S.

High-dose immunoglobulin replacement therapy by slow subcutaneous infusion during pregnancy.

JAMA. 1982; 247: 2824-2825Gardulf A. Andersson E. Lindqvist M. et al.

Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women.

J Clin Immunol. 2001; 21: 150-154Więsik-Szewczyk E. Jahnz-Różyk K.

A case report of pregnancy in a patient with common variable immunodeficiency emphasizing the need for personalized immunoglobulin replacement.

Medicine. 2018; 97: e12804

How I treat common variable immune deficiency.

Blood. 2010; 116: 7-15Egawa M. Kanegane H. Imai K. et al.

Intravenous immunoglobulin (IVIG) efficiency in women with common variable immunodeficiency (CVID) decreases significantly during pregnancy.

J Maternal-Fetal Neonatal Med. 2019; 32: 3092-3096Simister N.E. Mostov K.E.

An Fc receptor structurally related to MHC class I antigens.

Nature. 1989; 337: 184-187Firan M. Bawdon R. Radu C. et al.

The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans.

Int Immunol. 2001; 13: 993-1002Malek A. Sager R. Kuhn P. et al.

Evolution of maternofetal transport of immunoglobulins during human pregnancy.

Am J Reprod Immunol. 1996; 36 (New York, NY : 1989): 248-255Palmeira P. Quinello C. Silveira-Lessa A.L. et al.

IgG placental transfer in healthy and pathological pregnancies.

Clin Develop Immunol. 2012; 2012: 985646Costa-Carvalho B.T. Vieria H.M. Dimantas R.B. et al.

Transfer of IgG subclasses across placenta in term and preterm newborns.

Braz J Med Biol Res. 1996; 29: 201-204Skoda-Smith S. Torgerson T.R. Ochs H.D.

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.

Ther Clin Risk Manag. 2010; 6: 1-10Immune globulin (Intravenous, subcutaneous, and intramuscular). Drug information, 2021 (Accessed)

Intravenous immunoglobulin: adverse reactions and management.

J Allergy Clin Immunol. 2008; 122: 1238-1239Quinti I. Soresina A. Agostini C. et al.

Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration.

J Clin Immunol. 2008; 28: 263-267

Hematologic complications of primary immune deficiencies.

Blood Rev. 2002; 16: 61-64Sheikhbahaei S. Sherkat R. Camacho-Ordonez N. et al.

Pregnancy, child bearing and prevention of giving birth to the affected children in patients with primary immunodeficiency disease; a case-series.

BMC Pregnancy Childbirth. 2018; 18: 299

FDA. Safety & Availability (Biologics) > FDA Safety Communication: New boxed warning for thrombosis related to human immune globulin products. 2013.

(Available at:) (Accessed Dec 15, 2021)

Acute thromboembolic events associated with intravenous immunoglobulin infusion in antibody-deficient patients.

J Allergy Clin Immunol. 2003; 112: 797-799